ARTICLE | Clinical News
AEL completes Neovastat Phase III enrollment
December 18, 2001 8:00 AM UTC
Aeterna (TSE:AEL; AELA) completed enrollment in Europe and North America for a 280-patient Phase III trial of its Neovastat, an oral blocker of angiogenesis and inducer of apoptosis, to treat renal ce...